Drug Trial Radar · NCT03691623
A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
Last checked: Nov 19, 2026Latest source record: May 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
179
Actual
Start
Oct 15, 2018
Primary completion
Sep 30, 2019
Study completion Oct 18, 2019
Sponsor
- Lead sponsor
- Enanta Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- Collaborators
- hVIVO Services Limited
- First posted
- Oct 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to compare the antiviral effect of EDP-938 compared to a placebo control in the respiratory syncytial virus challenge model.
Conditions
- RSV Infection
Interventions
EDP-938 Dose 1Drug
Oral suspension for 5 days
EDP-938 Dose 2Drug
Oral suspension for 5 days
PlaceboDrug
Oral suspension for 5 days
EDP-938 Dose 3Drug
Oral suspension for 5 days
EDP-938 Dose 4Drug
Oral suspension for 5 days
PlaceboDrug
Oral suspension for 5 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral LoadTime frame: Twice daily on Day 2 through Day 11 and once on Day 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
hVIVO Services Limited (hVIVO)
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.